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Objective: to describe clinical and laboratory characteris-
tics; to assess predictors for death in HIV-infected
patients with Kaposi sarcoma (KS).
We performed a retrospective study of HIV-infected
patients diagnosed with KS in one infectious diseases hos-
pital in Romania, between January 2008-November 2013.
KS diagnosis was established on physical examination,
skin biopsy, and for visceral involvement upper gastroin-
testinal endoscopy, bronchoscopy and computed tomogra-
phy. KS was staged according to the AIDS Clinical
Trials Group (ACTG) [1] and the Mitsuyasu classification
system [2].
We identified 27 HIV-infected patients with KS. The
median age was 42 years (IQR 34-52) and 18 (67%) were
male. The median CD4 count at HIV diagnosis was 195
cells/cmm (IQR 55-313), while at KS diagnosis the median
CD4 count was 101 cells/cmm (IQR 41-270). Eighteen
(67%) patients had a CD4 count <200 cells/cmm. The
median HIV viral load at the time of KS diagnosis was
120,000 copies/mL (IQR 316-328,522). HIV infection was
diagnosed before KS in 19 patients (70%), with a median
time between HIV and KS diagnosis of 7 months (IQR
0-58). The most frequent KS localization was the lower
limb in 16 (59%) patients and 7 (26%) patients had disse-
minated KS. Oral, gastrointestinal and pulmonary involve-
ments were seen in 10 (37%), 4 (15%) and 3 (11%) patients
respectively. Concomitant opportunistic infections were
diagnosed in 20 (74%), while other malignancies in
3 (12%) patients. According to the ACTG classification 16
(59%) patients had poor risk KS. Fifteen (56%), 6 (22%),
1 (4%) and 5 (18%) were in stage 1, 2, 3 and 4, respectively
according to the Mitsuyasu classification. Six (22%)
patients received specific KS treatment: three local
radiotherapy and three systemic therapy (two with
interferon; one with liposomal doxorubicin). The overall
mortality was 41% with a median duration between KS
diagnosis and death of 6 months (IQR 2-15). Gastrointest-
inal involvement (p=0.019), poor-risk KS in ACTG classifi-
cation (p<0.001) and stage IV Mitsuyasu (p=0.006) were
associated with death in univariate analysis.
The mortality rate in this study was high, due to poor
immunological status, extended KS and high incidence of
opportunistic infections, but also due to the lack of specific
systemic treatment.
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